AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24603218 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear Magnetic Resonance Spectroscopy (NMR)
Number of subjects: 136
Study 24603218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ion Mobility
Number of subjects: 136
Study 24604476 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 60 mg once daily plus asunaprevir 100 mg twice daily for 24 weeks
Number of subjects: 222
Study 24604486 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic stone protein (PSP) and pancreatitis-associated protein (PAP) measured using a validated ELISA
Number of subjects: 160
Study 24604486 — intervention group
Group type: COMPARATOR
Intervention: Regular inflammatory markers (c-reactive protein, procalcitonin, interleukin-6, tumour necrosis factor-α, leucocyte counts)
Number of subjects: 160
Study 24604486 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intensive care unit days and total length of stay
Number of subjects: 160
Study 24606093 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin extended release 1500 mg/d for 12 weeks
Number of subjects: 36
Study 24606096 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 12098
Study 24606096 — intervention group
Group type: COMPARATOR
Intervention: No Growth Hormone (GH) treatment (Control)
Number of subjects: 12098
Study 24606326 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus rituximab
Number of subjects: 30
Study 24606567 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oral dose of trametinib
Number of subjects: 4
Study 24606567 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 μg radiolabelled i.v. microdose of trametinib
Number of subjects: 4
Study 24606768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/day plus trastuzumab (loading, 4 mg/kg; then weekly 2 mg/kg or loading, 8 mg/kg; then 3-weekly 6 mg/kg)
Number of subjects: 60
Study 24606768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg/day plus trastuzumab
Number of subjects: 60
Study 24606768 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib plus trastuzumab
Number of subjects: 60
Study 24606983 — intervention group
Group type: EXPERIMENTAL
Intervention: Thimerosal-containing QIV
Number of subjects: 56
Study 24606983 — intervention group
Group type: COMPARATOR
Intervention: Thimerosal-containing TIV (historical control)
Number of subjects: 56
Study 24607068 — intervention group
Group type: EXPERIMENTAL
Intervention: sifap1 study (5023 patients)
Number of subjects: 5023
Study 24607068 — intervention group
Group type: COMPARATOR
Intervention: GQH registry (17007 patients)
Number of subjects: 5023
Study 24607068 — intervention group
Group type: EXPERIMENTAL
Intervention: sifap1 study (4467 patients with ischaemic stroke or TIA)
Number of subjects: 5023
Study 24607068 — intervention group
Group type: COMPARATOR
Intervention: GQH registry (14522 patients with ischaemic stroke or TIA)
Number of subjects: 5023
Study 24607068 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 5023
Study 24607242 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral baclofen (titrated from 2.5 mg 3 times a day to a maximum of 20 mg 4 times a day)
Number of subjects: 49
Study 24607558 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenem exposure in AML patients
Number of subjects: 375
Study 24607558 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbapenem exposure in aSCT recipients
Number of subjects: 375
Study 24607558 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous exposure to carbapenems in both groups
Number of subjects: 375
Study 24607558 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence rates for CDI
Number of subjects: 375
Study 24607558 — intervention group
Group type: EXPERIMENTAL
Intervention: Median time from initiation of chemotherapy to CDI
Number of subjects: 375
Study 24607560 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/STI services integrated with MCH care
Number of subjects: 8263
Study 24607560 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV counselling
Number of subjects: 8263
Study 24607560 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/STI services with MCH care
Number of subjects: 8263
Study 24607560 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of HIV services with ANC, CH, and FP
Number of subjects: 8263
Study 24607560 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV/Pnc integration
Number of subjects: 8263
Study 24607562 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of the impact of acute exacerbations of COPD (AECOPD) on health-related quality of life and healthcare resource utilization.
Number of subjects: 0
Study 24607562 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular diagnostic and typing techniques to describe the dynamics of airway infection during AECOPD and stable disease.
Number of subjects: 0
Study 24607562 — intervention group
Group type: EXPERIMENTAL
Intervention: Refinement of the case definition of AECOPD to reflect possible microbiological aetiology.
Number of subjects: 0
Study 24607563 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary catheterisation or PCI
Number of subjects: 11900
Study 24607961 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level recreational activity
Number of subjects: 2
Study 24607961 — intervention group
Group type: COMPARATOR
Intervention: Sedentary lifestyle
Number of subjects: 2
Study 24609004 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured patient education program
Number of subjects: 50
Study 24609004 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured patient education program)
Number of subjects: 50
Study 24609004 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between groups at 3 months
Number of subjects: 50
Study 24609004 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between groups at 6 months
Number of subjects: 50
Study 24609004 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline health related quality of life scores
Number of subjects: 50
Study 24609720 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitivity IGF-1 measurement
Number of subjects: 52
Study 24609720 — intervention group
Group type: EXPERIMENTAL
Intervention: Refeeding index (RI)
Number of subjects: 52
Study 24609720 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin alone
Number of subjects: 52
Study 24610188 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene Expression Score (GES) testing
Number of subjects: 251
Study 24610431 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 488
Study 24610431 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (sertraline; SRT)
Number of subjects: 488
Study 24610431 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CBT and medication (COMB)
Number of subjects: 488
Study 24610431 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 488
Study 24610872 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 312
Study 24610872 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 312
Study 24612927 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin for patients with positive RUT
Number of subjects: 347
Study 24612927 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Number of subjects: 347
Study 24612927 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 347
Study 24612927 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 347
Study 24612927 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam
Number of subjects: 347
Study 24612927 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic use of RUT
Number of subjects: 347
Study 24613652 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical and Mental Health Unit
Number of subjects: 60
Study 24613652 — intervention group
Group type: COMPARATOR
Intervention: Standard care wards
Number of subjects: 60
Study 24613995 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine administration to a carrier of the p.A997T-NaV1.5 mutation (1 individual)
Number of subjects: 584
Study 24613995 — intervention group
Group type: EXPERIMENTAL
Intervention: SCN5A mutations (13 of 584 patients, 2.2%)
Number of subjects: 584
Study 24613995 — intervention group
Group type: EXPERIMENTAL
Intervention: Diarrhea-predominant IBS
Number of subjects: 584
Study 24613995 — intervention group
Group type: EXPERIMENTAL
Intervention: Constipation-predominant IBS
Number of subjects: 584
Study 24613995 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiologic analysis of NaV1.5 function
Number of subjects: 584
Study 24613995 — intervention group
Group type: COMPARATOR
Intervention: Genome-wide association study
Number of subjects: 584
Study 24614108 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine infusion during PDAC resection
Number of subjects: 122
Study 24614108 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative gemcitabine-based chemoradiotherapy
Number of subjects: 122
Study 24614178 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential radioembolization-sorafenib therapy (sorafenib 400 mg twice-daily initiated 14 days post-radioembolization with yttrium-90 resin microspheres).
Number of subjects: 29
Study 24614178 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential radioembolization-sorafenib therapy (sorafenib 600 mg median dose/day for a median duration of 4.1 months).
Number of subjects: 29
Study 24614178 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential radioembolization-sorafenib therapy (with 90Y-microspheres).
Number of subjects: 29
Study 24614383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine (doses ranging from 450 to 1800 mg)
Number of subjects: 0
Study 24614383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine (once-daily dosing over 14 days)
Number of subjects: 0
Study 24614383 — intervention group
Group type: EXPERIMENTAL
Intervention: Divided dosing of rifapentine
Number of subjects: 0
Study 24614383 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine (compartmental model)
Number of subjects: 0
Study 24614574 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 RM loading (relative load)
Number of subjects: 17
Study 24614574 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 RM loading (relative load)
Number of subjects: 17
Study 24614574 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 RM loading (relative load)
Number of subjects: 17
Study 24614574 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% contraction failure
Number of subjects: 17
Study 24614574 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% contraction failure
Number of subjects: 17
Study 24614574 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting knee pain after final repetition
Number of subjects: 17
Study 24614947 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,000 mg/m²) plus Cisplatin (25 mg/m²) on days 1 and 8, every 3 weeks for up to 24 weeks
Number of subjects: 18
Study 24615776 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib (GS-1101, CAL-101) taken once or twice daily at doses ranging from 50 to 350 mg.
Number of subjects: 64
Study 24615776 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib (GS-1101, CAL-101)
Number of subjects: 64
Study 24615777 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib (GS-1101, CAL-101) at 6 dose levels (50-350 mg once or twice daily)
Number of subjects: 54
Study 24615777 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib (GS-1101, CAL-101)
Number of subjects: 54
Study 24615778 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib (50-350 mg daily or twice daily)
Number of subjects: 40
Study 24615778 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib
Number of subjects: 40
Study 24616160 — intervention group
Group type: EXPERIMENTAL
Intervention: RUNX1-RUNX1T1 DNA quantification using real-time quantitative PCR
Number of subjects: 22
Study 24616160 — intervention group
Group type: COMPARATOR
Intervention: RUNX1-RUNX1T1 RNA detection
Number of subjects: 22
Study 24616160 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD monitoring on genomic DNA
Number of subjects: 22
Study 24616310 — intervention group
Group type: EXPERIMENTAL
Intervention: Mogamulizumab (1.0 mg/kg) administered intravenously once per week for 8 weeks
Number of subjects: 38
Study 24617713 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib (tyrosine kinase inhibitor)
Number of subjects: 1
Study 24618504 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetically guided capsule gastroscopy
Number of subjects: 189
Study 24618504 — intervention group
Group type: COMPARATOR
Intervention: Conventional gastroscopy
Number of subjects: 189
Study 24618589 — intervention group
Group type: EXPERIMENTAL
Intervention: GC1008 (fresolimumab) at doses of 0.1, 0.3, 1, 3, 10, or 15 mg/kg administered intravenously on days 0, 28, 42, and 56, followed by Extended Treatment of 4 doses every 2 weeks for up to 2 additional courses.
Number of subjects: 29
Study 24619017 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation (APBI) using external beam three-dimensional conformal radiotherapy (3D-CRT) at a total dose of 36.9 Gy (nine fractions of 4.1 Gy b.i.d.)
Number of subjects: 44
Study 24619017 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation (APBI) using external beam three-dimensional conformal radiotherapy (3D-CRT)
Number of subjects: 44
Study 24619321 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined arm (behavioral and medication management)
Number of subjects: 591
Study 24619321 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral arm
Number of subjects: 591
Study 24619321 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management arm
Number of subjects: 591
Study 24619321 — intervention group
Group type: COMPARATOR
Intervention: Combined arm
Number of subjects: 591
Study 24619321 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 591
Study 24620740 — intervention group
Group type: EXPERIMENTAL
Intervention: External cephalic version (ECV)
Number of subjects: 0
Study 24620740 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear for ECV and depression (measured by EDS scores)
Number of subjects: 0
Study 24620740 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstetric factors (parity, placental location, BMI, engagement of fetal breech)
Number of subjects: 0
Study 24620740 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear for ECV
Number of subjects: 0
Study 24620844 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtered P-SAECG signal
Number of subjects: 90
Study 24620844 — intervention group
Group type: EXPERIMENTAL
Intervention: Y lead
Number of subjects: 90
Study 24620844 — intervention group
Group type: EXPERIMENTAL
Intervention: Z lead
Number of subjects: 90
Study 24620844 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 90
Study 24620844 — intervention group
Group type: EXPERIMENTAL
Intervention: Interatrial fat
Number of subjects: 90
Study 24621049 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic spinal cord injury (SCI) participants
Number of subjects: 200
Study 24621121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled polymerase chain reaction (PCR) testing
Number of subjects: 0
Study 24621121 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled PCR testing
Number of subjects: 0
Study 24621973 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary tubular markers (NAG, KIM-1, NGAL)
Number of subjects: 2011
Study 24621973 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary KIM-1
Number of subjects: 2011
Study 24621973 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening renal function (WRF)
Number of subjects: 2011
Study 24621973 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline glomerular filtration rate
Number of subjects: 2011
Study 24621973 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary KIM-1, NAG, NGAL levels
Number of subjects: 2011
Study 24622344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer + weekly prompts + SDT grounded texts
Number of subjects: 160
Study 24622344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer + weekly prompts
Number of subjects: 160
Study 24622344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer only
Number of subjects: 160
Study 24622344 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 160
Study 24622396 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV MAARI
Number of subjects: 1642
Study 24622396 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient lower respiratory tract illness
Number of subjects: 1642
Study 24622396 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency department visits
Number of subjects: 1642
Study 24622396 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization (RSVH)
Number of subjects: 1642
Study 24622396 — intervention group
Group type: EXPERIMENTAL
Intervention: Daycare attendance or nonmultiple-birth, preschool-aged siblings
Number of subjects: 1642
Study 24622396 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronologic age <3 months
Number of subjects: 1642
Study 24622644 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide applied in 8 logarithmically increasing concentrations (0-100 μg/ml) on subject's forearm.
Number of subjects: 27
Study 24622709 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 24622709 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 24622806 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk diet (semiskimmed milk-based diet, 1700 mg Ca/d)
Number of subjects: 15
Study 24622806 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheese diet (semihard cow-cheese-based diet, 1700 mg Ca/d)
Number of subjects: 15
Study 24622806 — intervention group
Group type: COMPARATOR
Intervention: Control diet (nondairy diet, ~500 mg Ca/d)
Number of subjects: 15
Study 24623282 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib, 150 mg/d for a mean of 18.0 months (range, 11-24 months)
Number of subjects: 6
Study 24623833 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc monotherapy for 10 days
Number of subjects: 40
Study 24624090 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (0.8-3.3 mg/min)
Number of subjects: 24
Study 24624090 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine infusion (0.02-0.07 mg/min)
Number of subjects: 24
Study 24624891 — intervention group
Group type: EXPERIMENTAL
Intervention: AKDN classification
Number of subjects: 15773
Study 24624891 — intervention group
Group type: EXPERIMENTAL
Intervention: KDIGO classification
Number of subjects: 15773
Study 24624891 — intervention group
Group type: COMPARATOR
Intervention: NKF's KDOQI classification
Number of subjects: 15773
Study 24624930 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention (n=54)
Number of subjects: 157
Study 24624930 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise intervention (n=54)
Number of subjects: 157
Study 24624930 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=49)
Number of subjects: 157
Study 24624979 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-modifying therapy (DMT) compliance measured through pharmacy drug shipment records.
Number of subjects: 2966
Study 24624979 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate and beta-interferons (half of the sample using each).
Number of subjects: 2966
Study 24625556 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense chemoimmunotherapy with central nervous system prophylaxis
Number of subjects: 51
Study 24625556 — intervention group
Group type: EXPERIMENTAL
Intervention: COMMD1 expression
Number of subjects: 51
Study 24625556 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemical analysis of COMMD1 expression
Number of subjects: 51
Study 24625687 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a 44 mcg subcutaneously (IFN β-1a SC) three times weekly
Number of subjects: 23
Study 24625687 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 23
Study 24626872 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam for inhalation solution
Number of subjects: 89
Study 24626872 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life Questionnaire-Bronchiectasis (QOL-B) V3.0
Number of subjects: 89
Study 24626885 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients with mild OSA (n=39)
Number of subjects: 105
Study 24626885 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients with moderate to severe OSA (n=39)
Number of subjects: 105
Study 24626885 — intervention group
Group type: COMPARATOR
Intervention: Non-obese patients with mild OSA (n=66)
Number of subjects: 105
Study 24626885 — intervention group
Group type: COMPARATOR
Intervention: Non-obese patients with moderate OSA (n=66)
Number of subjects: 105
Study 24626999 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipoint pacing (MPP)
Number of subjects: 40
Study 24626999 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiac resynchronization therapy (CRT)
Number of subjects: 40
Study 24627116 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial B-mode ultrasound for volume estimation of hematoma
Number of subjects: 25
Study 24627116 — intervention group
Group type: EXPERIMENTAL
Intervention: Early hematoma expansion (EHE)
Number of subjects: 25
Study 24627116 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological deterioration
Number of subjects: 25
Study 24627116 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot sign positive patients
Number of subjects: 25
Study 24627116 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot sign negative patients
Number of subjects: 25
Study 24627436 — intervention group
Group type: EXPERIMENTAL
Intervention: high-specific-activity carrier-free (123)I-iobenguane
Number of subjects: 12
Study 24627529 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP cut-off value of 600 pg·mL(-1)
Number of subjects: 688
Study 24627529 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP ≥ 600 pg·mL(-1)
Number of subjects: 688
Study 24628565 — intervention group
Group type: EXPERIMENTAL
Intervention: BD Drihep A-Line
Number of subjects: 25